A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 1, 2008, Pages 171-177

  Rapp, Maryse ^a   Maurizis, Jean C ^a   Papon, Janine ^a   Labarre, Pierre ^a   Wu, Ting Di ^c,d   Croisy, Alain ^c,d   Guerquin Kern, Jean L ^c,d   Madelmont, Jean C ^a   Mounetou, Emmanuelle ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c INSTITUT CURIE   (France)

^d Centre Universitaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 (4 IODOBENZYLOXY) 9 [4 (DIETHYLAMINO)ETHYLCARBAMOYLBENZYL] PURINE; ANTINEOPLASTIC AGENT; BENZENE DERIVATIVE; CYSTEMUSTINE; ENZYME INHIBITOR; N,N DIETHYLAMINOETHYLENEBENZAMIDO; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; N' (2 CHLOROETHYL) N (2 (METHYLSULFONYL)ETHYL) N' NITROSOUREA; N'-(2-CHLOROETHYL)-N-(2-(METHYLSULFONYL)ETHYL)-N'-NITROSOUREA; NITROSOUREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CHEMOSENSITIVITY; DRUG DISPOSITION; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MASS SPECTROMETRY; MELANOMA; MELANOMA B16; MELANOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL DESTRUCTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; XENOGRAFT; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; EXPERIMENTAL MELANOMA; METABOLISM; METHODOLOGY; PHYSIOLOGY; REPRODUCIBILITY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; NITROSOUREA COMPOUNDS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; REPRODUCIBILITY OF RESULTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 45749123421     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.137737     Document Type: Article

References (30)

1. 2-acetylguanosine association. Melanoma Res 8:123-130.
2. Cure H, Souteyrand R, Ouabdesselam R, Roche H, Ravaud A, Viens P, Lentz MA, Fumoleau P, Hanauske A, and Chollet P (1999) Results of a phase II trial with cystemustine at 90 md/sq m in advanced malignant melanoma, first or second line: a trial of the Early Clinical Studies Group. Melanoma Res 9:607-610.
3. 6-benzyl-N-acetylguanosine derivatives of chloroethylnitrosourea antitumor action in chloroethylnitrosourea-resistant human malignant melanocytes. J Pharmacol Exp Ther 271:1353-1358.
4. 6-alkylguanine-DNA alkyltransferase inhibitor in nude mice bearing human melanoma. Drug Metab Dispos 22:637-642.
5. 6-benzyl-N2- acetylguanosine of N′-[2-chloroethyl]-N-[2-(methylsulphonyl)ethyl]- N′-nitrosourea therapeutic index on nude mice bearing resistant human melanoma. Br J Cancer 76:1157-1162.
6. Guerquin-Kern JL, Hillion F, Mademont JC, Labarre P, Papon J, and Croisy A (2004) Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences. Biomed Eng Online 3:10-15.
7. Guerquin-Kern JL, Wu TD, Quintana C, and Croisy A (2005) Progress in analytical imaging of the cell by dynamic secondary ion mass spectrometry. Biochim Biophys Acta 1724:228-238.
8. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
9. Jacubovich R and Doré JF (1979) Tumour-associated antigens in culture medium of malignant melanoma cell strains. Cancer Immunol Immunother 7:59-64.
10. 6-methylguanine-DNA methyltransferase (MGMT) to sensitize cancer cells to anticancer therapy. Expert Opin Ther Targets 11:349-361.
11. 6- methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J Pharmacol Exp Ther 311:585-593.
12. Labarre P, Papon J, Moreau MF, Madelmont JC, and Veyre A (1999) Evaluation in mice of some iodinated melanoma imaging agents using cryosectioning and multiwire proportional counting. Eur J Nucl Med 26:494-498.
13. Labarre P, Papon J, Moreau MF, Moins N, Bayle M, Veyre A, and Madelmont JC (2002) Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent. Melanoma Res 12:115-121.
14. Larson SM and Krenning EP (2005) A pragmatic perspective on molecular targeted radionuclide therapy. J Nucl Med 46:1S-3S.
15. Madelmont JC (1994) Cystemustine. Drugs Future 19:27-30.
16. 6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects. Int J Cancer 91:60-66.
17. 6- alkylguanine-DNA alkyltransferase inactivation in cancer chemotherapy. Mini Rev Med Chem 3:471-485.
18. Michelot JM, Moreau MFC, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, Bussiere F, Souteyrand PA, Mauclaire LP, Chossat FM, et al. (1993) Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J Nucl Med 34:1260-1266.
19. Miller AG and Mihnn MC (2006) Melanoma. N Engl J Med 355:51-65.
20. Moreau MF, Michelot J, Veyre A, Madelmont JC, Godenèche D, Labarre P, Parry D, and Meyniel G (1993) inventors. Agents for diagnosing and treating melanomas aromatic halogenated derivatives usable as such agents and their preparation. U.S. patent 5,190,741. 1993 Feb 3.
21. 6-alkylguanine-DNA alkyltransferase activity. J Labelled Compds Radiopharm 36:1215-1225.
22. 6-(alkyl/aryl)guanosine and 2′-deoxyguanosine derivatives: synthesis and ability to enhance chloroethylnitrosourea antitumor action. J Med Chem 40:2902-2909.
23. 4-benzylpteridine derivatives: alkylguanine-DNA alkyltransferase. J Med Chem 47:3887-3891.
24. 6-Methylguanine-DNA methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol 211:97-105.
25. 6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20:2277-2283.
26. 6-alkylguanine-DNA alkyltransferase: Phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 12:1577-1584.
27. 6-methylguanine-DNA methyltransferase. J Gene Med 8:972-979.
28. Tsutsumida A, Furukawa H, Yamamoto Y, and Sugihara T (2005) Treatment strategy for cutaneous malignant melanoma. Int J Clin Oncol 10:311-317.
29. 6-alkylguanine-DNA alkyltransferase. Bioconjug Chem 15:402-408.
30. 6-benzyl- 2′-deoxyguanosine (2005) J Med Chem 48:256-261.